Skip to main content
Signal8

Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

$PTNPress releaseNov 16, 2026, 7:30 AM ETRead the release

Palatin Technologies presented new preclinical data at ObesityWeek 2026 showing its next-generation MC4R-selective peptide agonists deliver potent weight-loss activity with minimal to no MC1R activity. The selectivity (over 100- to 200-fold for MC4R over MC1R) supports the goal of reducing or eliminating hyperpigmentation, a known limitation of approved MC4R therapies, while its lipidation technology enables once-weekly or less frequent dosing.

Key figures

Drug Name
PL2001
Phase Of Trial
Preclinical (first-in-human targeted H1 2027)
Dog half life lipidated
greater than 168 hours
Non lipidated half life
approximately two hours
Mc4r over mc1r selectivity
greater than 100-fold to greater than 200-fold
Rodent half life lipidated
approximately 24 hours

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.